Last reviewed · How we verify
Linezolid antimicrobial-lock solution
Linezolid antimicrobial-lock solution is a Oxazolidinone antibiotic Small molecule drug developed by Clinica Universidad de Navarra, Universidad de Navarra. It is currently FDA-approved for Prevention of catheter-related bloodstream infections in central venous catheters, Treatment of biofilm-associated infections on indwelling catheters. Also known as: linezolid: zyloxid 2 mg/ml, 300 ml vial., sodium heparin 1%, 5000 IU/5ml., sodium chloride 0,9% 10 ml vial..
Linezolid inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing peptide bond formation and bacterial growth.
Linezolid inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing peptide bond formation and bacterial growth. Used for Prevention and treatment of central venous catheter-related bloodstream infections, Catheter lock therapy for hemodialysis and other central lines.
At a glance
| Generic name | Linezolid antimicrobial-lock solution |
|---|---|
| Also known as | linezolid: zyloxid 2 mg/ml, 300 ml vial., sodium heparin 1%, 5000 IU/5ml., sodium chloride 0,9% 10 ml vial. |
| Sponsor | Clinica Universidad de Navarra, Universidad de Navarra |
| Drug class | Oxazolidinone antibiotic |
| Target | Bacterial 50S ribosomal subunit |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Linezolid is an oxazolidinone antibiotic that binds to the bacterial 50S ribosomal subunit and inhibits the initiation of protein synthesis. This bacteriostatic mechanism is effective against a broad spectrum of gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE). When formulated as an antimicrobial-lock solution, it is instilled into central venous catheters to prevent biofilm formation and catheter-related bloodstream infections.
Approved indications
- Prevention of catheter-related bloodstream infections in central venous catheters
- Treatment of biofilm-associated infections on indwelling catheters
Common side effects
- Thrombocytopenia
- Peripheral neuropathy
- Optic neuropathy
- Serotonin syndrome (with concurrent serotonergic agents)
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Linezolid antimicrobial-lock solution CI brief — competitive landscape report
- Linezolid antimicrobial-lock solution updates RSS · CI watch RSS
- Clinica Universidad de Navarra, Universidad de Navarra portfolio CI
Frequently asked questions about Linezolid antimicrobial-lock solution
What is Linezolid antimicrobial-lock solution?
How does Linezolid antimicrobial-lock solution work?
What is Linezolid antimicrobial-lock solution used for?
Who makes Linezolid antimicrobial-lock solution?
Is Linezolid antimicrobial-lock solution also known as anything else?
What drug class is Linezolid antimicrobial-lock solution in?
What development phase is Linezolid antimicrobial-lock solution in?
What are the side effects of Linezolid antimicrobial-lock solution?
What does Linezolid antimicrobial-lock solution target?
Related
- Drug class: All Oxazolidinone antibiotic drugs
- Target: All drugs targeting Bacterial 50S ribosomal subunit
- Manufacturer: Clinica Universidad de Navarra, Universidad de Navarra — full pipeline
- Therapeutic area: All drugs in Infectious Disease
- Indication: Drugs for Prevention of catheter-related bloodstream infections in central venous catheters
- Indication: Drugs for Treatment of biofilm-associated infections on indwelling catheters
- Also known as: linezolid: zyloxid 2 mg/ml, 300 ml vial., sodium heparin 1%, 5000 IU/5ml., sodium chloride 0,9% 10 ml vial.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing